More News! 24 Oct 2022 Sensorion gets go-ahead from France for trial of drug to prevent hearing loss Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […] October 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Sensorion receives positive opinion from EMA for treatment of hearing loss The European Medicines Agency (EMA) through its Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for a treatment for otoferlin gene mediated hearing loss. Clinical-stage biotech, Sensorion, announced the news today (September 12) that its application for an Orphan Drug Designation (ODD) for its lead therapy gene candidate, OTOF-GT will now be […] September 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […] July 22, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Mogrify and Astellas to address sensorineural hearing loss Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Utilizing Mogrify’s direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Progress for hearing preservation trial after Australian approval granted Approval has been granted by the Australian authorities to allow a French company to progress with a clinical trial testing cochlear implants. Montpellier-based Sensorion will start its proof of concept trial of SENS-401, a drug candidate that aims to protect and preserve inner ear tissue from damage. Sensorion is a biotech company specializing in the […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email